InnoPharmax Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was TWD 48.06 million compared to TWD 136.88 million a year ago. Net loss was TWD 92.97 million compared to TWD 43.9 million a year ago. Basic loss per share from continuing operations was TWD 1.08 compared to TWD 0.57 a year ago. Diluted loss per share from continuing operations was TWD 1.08 compared to TWD 0.57 a year ago.